ALNYLAM PHARMACEUTICALS INC (ALNY) Stock News

USA - NASDAQ:ALNY - US02043Q1076 - Common Stock

449.16 USD

-4.81 (-1.06%)

Last: 11/14/2025, 8:00:00 PM

449.16 USD

0 (0%)

After Hours: 11/14/2025, 8:00:00 PM

Technical Analysis

Fundamental Analysis

Analyst Ratings

Earnings Estimates

ALNY Latest News, Press Relases and Analysis

All

Press Releases

17 days ago - By: Chartmill

News Image

Alnylam Pharmaceuticals Inc (NASDAQ:ALNY) Stock Dips Despite Blowout Q3 2025 Earnings

4 days ago - By: Benzinga - Mentions: NVO PFE PRTA

Novo Nordisk's $100 Million Coramitug Shows Promise In Reducing Heart Failure Biomarker

5 days ago - By: The Motley Fool - Mentions: TOST IONQ

Got $5,000? 3 Top Growth Stocks to Buy That Could Double Your Money

8 days ago - By: Alnylam Pharmaceuticals, Inc.

New Post Hoc Analysis from the HELIOS-B Phase 3 Study Shows Vutrisiran Improved Measures of Heart Structure and Function in Patients with ATTR-CM

9 days ago - By: Benzinga

Here's How Much $1000 Invested In Alnylam Pharmaceuticals 20 Years Ago Would Be Worth Today

9 days ago - By: Investor's Business Daily - Mentions: RY RY.CA NTLA CRSP ...

Intellia Therapeutics Crashes After A Patient In Its Pivotal Study Dies

12 days ago - By: Alnylam Pharmaceuticals, Inc.

Alnylam to Webcast Presentations at Upcoming November Investor Conferences

16 days ago - By: Zacks Investment Research - Mentions: BEAM FOLD

ALNY Q3 Earnings and Revenues Top Estimates on Higher Amvuttra Sales

17 days ago - By: Zacks Investment Research

Compared to Estimates, Alnylam (ALNY) Q3 Earnings: A Look at Key Metrics

17 days ago - By: Investor's Business Daily - Mentions: PFE BBIO IONS AZN

Alnylam Stock Has Already Doubled In 2025. Why It Could Rocket Again On Earnings.

17 days ago - By: Alnylam Pharmaceuticals, Inc.

Alnylam Pharmaceuticals Reports Third Quarter 2025 Financial Results and Highlights Recent Period Progress

18 days ago - By: Zacks Investment Research - Mentions: VRTX ZTS EXAS

Zoetis Gears Up to Report Q3 Earnings: Here's What to Expect

24 days ago - By: Zacks Investment Research - Mentions: ALKS VKTX HOWL

Viking Therapeutics Posts Wider-Than-Expected Loss in Q3, Sales Nil

24 days ago - By: Zacks Investment Research - Mentions: ADPT IQV

IQVIA Gears Up to Report Q3 Earnings: What's in the Cards?

24 days ago - By: Zacks Investment Research - Mentions: ARVN

Alnylam Pharmaceuticals (ALNY) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

24 days ago - By: Zacks Investment Research - Mentions: REGN ETNB

RHHBY's Sales Up 7% in First 9 Months of 2025, '25 Earnings View Raised

a month ago - By: Zacks Investment Research

Why Alnylam (ALNY) Might be Well Poised for a Surge

a month ago - By: Alnylam Pharmaceuticals, Inc.

Alnylam to Webcast Conference Call Discussing Third Quarter 2025 Financial Results

a month ago - By: DataM Intelligence 4 Market Research LLP

Cardiovascular Drugs Market Size to Reach US$ 247.8 Billion by 2033, Driven by Rising Cardiovascular Disease Cases and Lifestyle Changes | According to DataM Intelligence

2 months ago - By: Bloomberg - Mentions: BMY ABBV

Alnylam Pulls TV Ad After Trump Crackdown on Drug Industry Spots

2 months ago - By: Zacks Investment Research - Mentions: NVS PFE BBIO

Can Alnylam's Broader Portfolio Ease Its Dependence on Amvuttra?

2 months ago - By: Alnylam Pharmaceuticals, Inc.

Alnylam Announces First Patient Dosed in ZENITH Global Phase 3 Cardiovascular Outcomes Trial of Zilebesiran

2 months ago - By: Alnylam Pharmaceuticals, Inc.

New Data from HELIOS-B Phase 3 Study Demonstrate Lower Rates of Gastrointestinal Events in ATTR-CM Patients Treated with Vutrisiran

2 months ago - By: Investor's Business Daily - Mentions: XPH PPH XBI IBB ...

Pharma Tariffs Back In Spotlight On New Trump Threat

2 months ago - By: Illumina, Inc. - Mentions: ILMN

Alnylam Pharmaceuticals joins Alliance for Genomic Discovery, expanding diverse clinical genomic dataset to drive precision medicine